Data completeness
3/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIJOICE (alpelisib) is an oral small-molecule PI3K inhibitor approved by the FDA in April 2024 in a novel granule formulation. The drug treats patients with PIK3CA-mutant breast cancer and other solid tumors by inhibiting phosphatidylinositol 3-kinase signaling. This formulation represents a new delivery option for an established mechanism in oncology.
$6MPart D
Growth10.3 years to LOEEarly commercialization phase with modest initial uptake; brand teams should expect ramping demand as indication awareness grows and formulary access expands.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIJOICE positions professionals in a high-growth oncology launch at Novartis, a tier-1 pharma employer with robust infrastructure. The granule formulation innovation and early market phase create career visibility and impact potential in both commercial execution and medical strategy.
Brand ManagerOncology Sales Representative
Worked on VIJOICE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.